FDA Clears Investigational New Drug Application for Novel BD2-Selective BET Inhibitor, VYN202
Phase Ia trial of VYN202, expected to begin this quarter, will enroll approximately 64 healthy participants.
The FDA has cleared an Investigational New Drug Application (IND) for VYNE Therapeutics' VYN202, an oral BD2-selective BET inhibitor. VYNE plans to initiate a first-in-human Phase Ia single ascending dose/multiple ascending dose (SAD/MAD) trial in healthy volunteers this quarter with top line results expected in the second half of 2024.1
“VYN202 is a highly selective and potent orally administered BET inhibitor that we believe has significant potential as a treatment option for autoimmune diseases. Clearance of the IND for VYN202 marks a major step forward in this effort,” David Domzalski, president and CEO of VYNE said in a press release. “We look forward to initiating the Phase Ia trial in the coming weeks to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.”
In October 2023, VYNE reported positive results from preclinical studies of VYN202 in models of psoriasis and rheumatoid arthritis.2
“We believe VYN202 has the potential to be the most potent and selective BET inhibitor in development and has consistently demonstrated its ability to improve signs and symptoms of disease with marked inhibition of key inflammatory cytokines implicated in the pathology of several chronic autoimmune diseases in preclinical models,” Domzalski said in an earlier press release. “These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility in both psoriasis and rheumatoid arthritis. We look forward to advancing these programs into the clinic next year and updating investors on our progress.”
The Phase Ia clinical trial of VYN202 is a double-blind, placebo-controlled study in healthy volunteers and consists of SAD and MAD components. It is expected to enroll approximately 64 healthy adult participants, who will be split into five SAD and three MAD cohorts to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.
Looking forward, if this portion of the trial is successfully completed, VYNE plans to initiate Phase Ib trials in subjects with moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis, with top line results anticipated in the second half of 2025.
References
1. VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor. Press release. May 6, 2024. Accessed May 7, 2024. https://vynetherapeutics.com/press-releases/vyne-therapeutics-announces-fda-clearance-of-ind-application-for-vyn202-a-novel-bd2-selective-bet-inhibitor/
2. VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202. Press release. October 30, 2023. Accessed May 7, 2024. https://vynetherapeutics.com/press-releases/vyne-therapeutics-reports-positive-results-from-preclinical-models-for-oral-bd2-selective-bet-inhibitor-vyn202/
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
